March 31, 2020

Freezing of Gait Treatment Market outlook 2019 shows growth drivers, opportunities and forecast analysis to 2027

The freezing of the gait treatment market is expected to increase by 7.2% in the CAGR during the forecast period from 2019 to 2027.

The global market for Freezing of Gait Treatment is growing effectively from 2019 to 2027, accredited to the increase in admissions for PD-related patients in clinics and hospitals, along with improved medical care infrastructure on a global scale. The approval of new drugs and therapies, along with equipment and implants in the pipeline, the technology expansion of wearable and walking aid devices is driving the overall market growth.

Access Free Sample Copy of Research Report:

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

Effective management of neuroprotective therapy along with pharmacological PD therapy will slowly gain traction in the international market. Patients dealing with Freezing of Gait note that their feet feel stuck to the ground and may lead to imbalances and falls, such as fractures and hospital admissions. Freezing of gait can often be triggered by cognitive influences such as anxiety or distraction, or by passing through doorways, lifts, busy crowds, or tight spaces.

Research and development on top-quality drugs with increased costs in the end-user segment is driving overall growth. Freezing of Gait patients is greatly helped by levodopa/carbidopa. However, medications and therapies or exercises do not completely eliminate symptoms. Deep brain stimulation procedures are also used in a few cases. In Dec 2017, researchers from NUI Galway discovered a new device called ‘cueStim’ designed to help those living with gait freezing. It can electrically stimulate changes in the human body and can be controlled by Bluetooth or a smartphone device.

Top drug and equipment manufacturers focus mainly on new product launches and FDA approvals. Increasing partnerships with research centres and the strategic alliance of key players internationally will drive market growth in the near future. For example, in December 2018, Acorda Therapeutics, Inc. announced the FDA approval of INBRIJATM, inhaled levodopa for on-demand use for OFF periods in people with Parkinson’s disease taking levodopa/carbidopa. However, the high cost of treatment, the burden of PD with far fewer treatment options globally, less awareness of pipeline products and less favourable outcomes after a long life of treatment are few factors that hinder the growth of the global Freezing of Gait Treatment.

For Any Query, Ask Our Expert at:

Key Market Movements:

  • Globally, CAGR Freezing of Gait Treatment has increased by 7.2% over the period from 2019 to 2027.
    The U.S. market will gain traction due to its improved infrastructure, a large PD patient pool and FDA approval for new drugs.
  • The growing number of hospitals and clinics, strong pipeline products for freezing of gait treatment, and increased medical care expenditure in the emerging nations will drive the overall market growth.
  • Major players in this vertical are Acorda Therapeutics, Michael J. Fox Foundation, GYENNO, National University of Ireland Galway (NUI Galway), Kyungpook National University of Korea, MedEXO Robotics, Teva Pharmaceuticals and others.

Access Free Sample Copy of Research Report:

Leave a Reply

Your email address will not be published. Required fields are marked *